Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s ...

Tremfya is also under review in the EU for UC. Tremfya is under review in the United States and EU for the other IBD condition, CD. J&J expects Tremfya to be a $5 billion product with approvals in ...

Safety data were consistent with the well-established safety profile of TREMFYA ® in inflammatory bowel disease (IBD) with no new safety concerns identified. "With these findings, TREMFYA shows ...

J&J expects Tremfya to be a $5-billion product with potential approvals across both IBD indications. Year to date, J&J’s shares have moved up 5.1% compared with the industry’s 24.2% rise.

According to J&J's chair of innovative medicines, Jennifer Taubert, Tremfya has the profile needed to make headway in the IBD market. "It's the only dual-acting IL-23 agent in IBD, acting on both ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

How Does Tremfya Work for Crohn's Disease? Tremfya is a type of medicine called a monoclonal antibody. It works by targeting a protein in your body called interleukin-23 (IL-23). IL-23 is a ...

Wednesday, J&J said the FDA has granted approval for Tremfya in moderate to severely active ulcerative colitis (UC), a form of IBD that impacts more than 1.2 million Americans. The expanded label ...

"Data from the ASTRO study demonstrate that subcutaneous induction treatment with TREMFYA provides clinically meaningful remission in patients with ulcerative colitis, similar to the effects seen ...

The treatment is approved for people with moderate to severe forms of Crohn’s, a type of inflammatory bowel disease (IBD) that causes ... managing the disease. Tremfya is the first that also ...